NASDAQ: ANABAnaptysbio Inc Stock
$19.27+0.09 (+0.47%)
Updated Apr 24, 2024
ANAB Price
$19.27
Fair Value Price
-$13.81
Market Cap
$515.72M
52 Week Low
$13.36
52 Week High
$27.50
P/E
-3.17x
P/B
5.85x
P/S
33.61x
PEG
N/A
Dividend Yield
N/A
Revenue
$17.16M
Earnings
-$163.62M
Gross Margin
100%
Operating Margin
-953.68%
Profit Margin
-953.7%
Debt to Equity
4.14
Operating Cash Flow
-$121M
Beta
0.94
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ANAB Overview
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ANAB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ANAB ($19.27) is overvalued by 239.52% relative to our estimate of its Fair Value price of -$13.81 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ANAB ($19.27) is not significantly undervalued (239.52%) relative to our estimate of its Fair Value price of -$13.81 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ANAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ANAB due diligence checks available for Premium users.
Be the first to know about important ANAB news, forecast changes, insider trades & much more!
ANAB News
Valuation
ANAB fair value
Fair Value of ANAB stock based on Discounted Cash Flow (DCF)
Price
$19.27
Fair Value
-$13.81
Undervalued by
239.52%
ANAB ($19.27) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ANAB ($19.27) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ANAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ANAB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.17x
Industry
15.69x
Market
41.27x
ANAB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.85x
Industry
5.86x
ANAB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ANAB's financial health
Profit margin
Revenue
$9.0M
Net Income
-$42.2M
Profit Margin
-468.8%
ANAB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ANAB's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$452.4M
Liabilities
$364.3M
Debt to equity
4.14
ANAB's short-term assets ($406.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ANAB's short-term assets ($406.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ANAB's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ANAB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$34.3M
Investing
$49.2M
Financing
-$5.2M
ANAB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ANAB vs Biotech Stocks
Anaptysbio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.